Objective: The present study was designed to examine for the first time, side-by-side, the effects of plant sterol and stanol consumption on lipid metabolism and markers of antioxidant status, oxidative stress, endothelial dysfunction and low-grade inflammation in subjects on stable statin-treatment. Design: Double-blind, randomized, placebo-controlled, intervention trial. Setting: University. Subjects: Forty-five patients on current statin treatment were recruited via newspaper advertisements. Data of 41 patients were used in statistical analysis. Intervention: Subjects consumed margarine with no added plant sterols or stanols for 4 weeks and were then divided into three groups of 15 subjects. For the next 16 weeks, one group continued with the control margarine and the other two groups with either a plant sterol-or stanol (2.5 g/day)-enriched margarine. Blood was sampled at the end of the run-in and intervention periods. Results: Plant sterol and stanol consumption significantly (P ¼ 0.026) reduced low-density lipoprotein (LDL) cholesterol by 0.34 mmol/l (95% confidence interval (CI), À0.67 to À0.04 mmol/l). No effects were shown on enzymatic and non-enzymatic antioxidants and markers of oxidative modification of lipids and DNA. In addition, no effect was found on soluble adhesion molecules, C-reactive protein and monocyte chemotactic protein-1 concentrations. Conclusions: We conclude that 16 weeks of plant sterol or stanol consumption did not affect markers of antioxidant status, oxidative stress, endothelial dysfunction and low-grade inflammation in patients on stable statin treatment, despite a significant reduction of LDL cholesterol.
Introduction
Atherosclerosis, the underlying cause of cardiovascular diseases (CVDs), is related to low-grade systemic inflammation initiated by endothelial dysfunction, caused by factors such as elevated concentrations of oxidized cholesterol, smoking, obesity and diabetes. These factors may increase the permeability of the vessel wall for mononuclear cells as well as the production of cellular adhesion molecules, cytokines and growth factors, and thus initiate the process of low-grade inflammation in the arteries (Ross, 1999) . In support, increased plasma concentrations of circulating adhesion molecules and markers of low-grade systemic inflammation such as soluble vascular cell adhesion molecule 1 (sVCAM-1) (Peter et al., 1997) , intercellular adhesion molecule 1 (sICAM-1) and C-reactive protein (CRP) (Ridker et al., 2000) are associated with future events of CVD. As well treatment with drugs, such as the cholesterol-lowering statins (Liao and Laufs, 2005) and nutritional interventions, such as a diet high in a-linolenic acid, have been shown to lower circulating concentrations of sICAM, sVCAM and CRP (Zhao et al., 2004) , indicating the possibility to reverse endothelial dysfunction in response to interventions.
Plant sterols and stanols, which are structurally related to cholesterol, lower serum low-density lipoprotein (LDL) cholesterol levels and are nowadays added to a wide variety of foods known as functional foods. Moreover, they obtained a prominent position in the National Cholesterol Education Program guidelines for lowering coronary heart disease risk (Expert Panel on Detection, 2001 ). However, not much is known about the effects of plant sterols and stanols on markers of endothelial function or low-grade inflammation. Furthermore, plant sterols and stanols not only lower serum LDL cholesterol but may also decrease lipid-standardized concentrations of diet-derived hydrocarbon carotenoids (Katan et al., 2003) . Whether the decrease in these antioxidants has any further consequences is not known. In theory, it is possible that increased activity of enzymatic antioxidants compensate for the reduction in diet-derived carotenoids. However, it is also possible that markers of lipid peroxidation (oxidized LDL (oxLDL), malondialdehyde (MDA) and 15-keto-dihydro-prostaglandin F2a (15-PGDH)) and DNA damage 7-hydro-8-oxo-2-deoxyguanosine (8-oxo-dG) increase.
Therefore, in the present study, we have examined the effects of plant sterol or stanol consumption, not only on lipid and lipoprotein metabolism and plasma hydrocarbon carotenoid concentrations, but also on enzymatic antioxidant systems, plasma markers of oxidized lipids, DNA damage and markers of endothelial function and low-grade inflammation in subjects on current statin treatment.
Subjects and methods

Subjects
Subjects were recruited via posters in the university and hospital buildings and via local newspaper advertisements. Inclusion criteria were: current treatment with a 3-hydroxy-3-methyl-glutaryl-CoA (HMG-CoA) reductase inhibitor (statins), age 18-65 years, body mass index p32 kg/m 2 , no proteinuria or glucosuria, diastolic blood pressure p95 mm Hg and systolic blood pressure p200 mm Hg. Subjects with clinical manifestations of liver disorders, CVD (o6 months) and type II diabetes mellitus were excluded. Seventy-five subjects were interested and received an information brochure about the purpose and the protocol of the study. Subjects came to the university for two screening visits with an interval of at least 3 days. On both visits, fasting blood was sampled for analyses of serum total cholesterol and triacylglycerol concentrations, blood pressure was measured three times (of which the average was calculated) and height and body weight were determined. Furthermore, subjects had to complete a medical and general questionnaire. After screening, 45 patients on stable statin treatment met all of our criteria and started the study. Two subjects dropped out during the run-in period, because they could not consume the requested amount of margarine. Thus, 43 subjects (22 male and 21 female) completed the study. All women, except one, were postmenopausal. The Ethics Committee of the Maastricht University had approved the protocol and all subjects signed an informed consent.
Diets and design
Subjects were asked to replace their own margarine or butter with the 'light' margarines (40% fat) of which 30 g per day should be consumed, divided over at least two meals. For the first 4 weeks, subjects used control margarine without added plant sterols or stanols (run-in period). At the end of the runin period, subjects were randomly allocated to one of the three experimental groups, stratified for sex and age. The first group continued with the control margarine, the second group with a plant sterol-enriched margarine and the last group with a plant stanol-enriched margarine for 16 weeks. For the second and third groups, the daily intake of 30 g of margarine equaled an intake of 2.5 g plant sterols or stanols a day. Plant sterols and stanols were provided as fatty acid esters by transesterification of free plant sterols and stanols with rapeseed oil fatty acids. The plant sterol ester mixtures mainly contained sitosterol ester (49%), campesterol ester (31%) and stigmasterol ester (16%) and plant stanol mixtures were obtained by saturation of these sterols, giving sitostanol ester (69%) and campestanol ester (31%) (Raisio Group, Raisio, Finland). The margarine was packed in tubs of 220 g each, equivalent to margarine for 7 days. All products were coded with a color label to blind the subjects and the investigators. The volunteers came to the university at least every 3 weeks to receive the products and for measuring body weight (without shoes and heavy clothing). At the end of the week, the used tubs had to be set aside and returned to the department to be weighed back for the calculation of total margarine intake per week. At the end of the study, this information was used to calculate the average daily intake. At the end of the run-in and experimental periods, subjects completed a food frequency questionnaire (Plat and Mensink, 2000) , in which they recorded their food intake from the previous 4 weeks. The dietician checked these questionnaires and calculated the composition of the diet according to the Dutch food-composition table to estimate the energy and nutrient intake of the subjects. In a diary, the subjects wrote (Friedewald et al., 1972) . Apolipoprotein A-I (apoA-I) and apolipoprotein B (apoB) were measured using an immunoturbidimetric reaction (UNI-KIT apoA-I and UNI-KIT apoB; Roche, Basel, Swiss). Samples of weeks 3 and 4 and samples of weeks 19 and 20 were pooled before analyses of apoA-I and apoB. All samples from one subject were analyzed within the same run. The variation coefficients within runs were 3.2 for total cholesterol, 2.8 for triacylglycerol, 5.8 for HDL cholesterol, 2.6 for apoA-I and 1.6% for ApoB.
Plant sterols and cholesterol precursors Serum plant sterol (sitosterol, campesterol), plant stanol (sitostanol, campestanol) and cholesterol precursor (lathosterol) concentrations were analyzed by gas chromatography as described before (Plat and Mensink, 2001) . Serum samples of weeks 3 and 4 and weeks 19 and 20 were pooled before analysis. Samples of one subject were analyzed in the same analytical run. Plant sterol and stanol concentrations were expressed per mmol total cholesterol.
LDL-receptor mRNA
PBMCs were isolated from 20 ml EDTA blood by Lymphoprep density gradient centrifugation (Nycomed Pharma AS, Oslo, Norway) according to instructions of the manufacturer. The isolated cell pellet was taken up in 1500 ml Trizol (GIBCO, Invitrogen, Breda, The Netherlands) and immediately stored at -801C until further isolation according standard protocols. Following DNAse treatment (Promega Benelux B.V., Leiden, The Netherlands), cDNA was synthesized as described before (Plat and Mensink, 2002b) . LDLreceptor mRNA expression was determined by real-time PCR. Oligonucleotide primers and probes for both the LDL receptor (forward 5 0 -GAGAAGAAGCCCAGTAGCGTG, reverse 5 0 -GCTGTTGATGTTCTTAAGCCGC, probe 5 0 -TGTCC TCCCCATCGTGCTCCTC) and b-actin as housekeeping gene (forward 5 0 -AGCCTCGCCTTTGCCGA, reverse 5 0 -CTGGT GCCTGGGGCG, probe 5 0 -CCGCCGCCCGTCCACACCCG CC) were purchased from Sigma Genosys (UK). LDL receptor and b-actin mRNA concentrations from one subject before and after the intervention were always analyzed in duplo in the same analytical run. The temperature program consisted of 2 min at 501C, 10 min at 951C, and 45 cycles of 15 s at 951C and 1 min at 601C. To quantify the LDL-receptor expression, the comparative C T method (User Bulletin #2; ABI Prism 7700 Sequence Detection System, Applied Biosystems), in which the expression of the LDL receptor gene was normalized against the housekeeping gene b-actin, was used. The given difference resulted in the reported DDC T value.
Antioxidants and markers of endothelial function and low-grade inflammation At the end of the run-in period (weeks 3 and 4) and the experimental period (weeks 19 and 20) a broad spectrum of antioxidants and markers reflecting low-grade inflammation and endothelial (dys)function were measured in EDTA plasma. Soluble E-selectin and soluble ICAM were measured by enzyme-linked immunosorbent assay (ELISA) as described by Bouma et al. (1997) and Leeuwenberg et al. (1992) . Soluble VCAM-1 and MCP-1 were measured with commercially available ELISA kits (R&D Systems Europe Ltd, Abingdon, UK), according to the manufacturer's instructions. Hs-CRP was measured on Cobas Mira with a commercially available kit (Kamiya Biomedical Company, Seattle, WA, USA). For all performed assays, samples were analyzed in duplo.
Plasma-oxidized LDL concentrations were measured by a commercially available sandwich ELISA (Mercodia, Uppsala, Sweden) with the specific murine monoclonal antibody mAb-4E6 as described by Holvoet et al. (1998) . Tocopherols and carotenoids were analyzed by reversed-phase highperformance liquid chromatography (HPLC) as described before (Plat and Mensink, 2001) . As a marker for enzymatic lipid peroxidation, 15-PGDH was measured by radioimmunoassay as described before (Basu, 1998) . MDA was measured in plasma using a fluorescent thiobarbituric acid assay as described before (Lepage et al., 1991) (Guillen-Sans and Guzman-Chozas, 1998). To assess oxidative DNA damage, DNA was isolated from PBMCs by the QIAmp DNA Blood Midi Kit (QIAgen Benelux B.V., Venlo, The Netherlands) and subsequently 8-oxo-dG was determined by HPLC with electrochemical detection (Briede et al., 2004) . Finally, erythrocyte samples were analyzed for erythrocyte glutathione concentrations as described by Paglia and Valentine (1967) and Flohe and Gunzler (1984) . The analyses of catalase concentrations (Aebi, 1984) and superoxide dismutase (SOD) activities (Kirkova et al., 1999) were performed as described before.
Clinical safety parameters and hematological measurements
Concentrations of liver and kidney enzymes (total bilirubin, ASAT, ALAT, alcalic phosphatase, g-GT and creatinine) were determined at the Department of Clinical Chemistry, University Hospital Maastricht, Maastricht, The Netherlands (Beckman Synchron CX7 Clinical Systems, Beckman). Various hematological parameters (white blood cell count, percentages and numbers of lymphocytes, mononuclear cells and granulocytes, RBC count, hemoglobin concentration, hematocrit, mean corpuscular volume, platelet count and platelet volume) were determined by using a Coulter Counter (Coulter MD series, Beckmann Coulter Inc., Miami, FL, USA). None of these parameters were affected by the treatments (data not shown).
Statistics
Forty-three subjects completed the study. The results of two subjects were however excluded from the statistical analyses. For one subject from the control group, the statin dose was doubled (from 20 to 40 mg simvastatin) during the study, whereas a second subject from the control group was excluded because he did not consume the requested amount of margarine and did not come to the appointments of the last 4 weeks. Thus, the statistical analyses were performed on the results of 41 subjects, 20 males and 21 females.
The responses to treatment for each subject were calculated as the difference between values obtained at the end of the experimental period (means of values of weeks 19 and 20) and the run-in period (means of values of weeks 3 and 4). Differences in changes between the treatment groups were analyzed by one-way analysis of variance. When a significant diet effect was found, treatments were compared pair wise and corrected for three group comparisons (a ¼ 0.017) using the Bonferroni multicomparison test. Contrast analysis was performed to analyze the effects of plant sterol and stanol consumption as a group against the control group (a ¼ 0.05). All statistical analyses were performed with SPSS 11.0 for Mac Os X (SPSS Inc., Chigaco, CA, USA).
Results
Dietary intakes, margarine consumption and body weight Table 1 shows that baseline characteristics were not significantly different between subjects of the control and intervention groups. Energy intake and the proportions of energy from carbohydrates, fatty acids and proteins as well as cholesterol intake did not change significantly during the study (Table 2) . Mean estimated daily intake of the 
Plant sterols and cholesterol precursors
As expected, plant sterol consumption increased cholesterolstandardized campesterol concentrations significantly by 59% (P ¼ 0.004) as compared with changes in the control group. Also cholesterol-standardized sitosterol concentrations increased by 42% as compared with the control group (P ¼ 0.022). In contrast, plant stanol consumption decreased cholesterol-standardized concentrations of campesterol (84%) and sitosterol (64%) significantly (po0.001) as compared with the plant sterol group. Cholesterol-standardized sitostanol and campestanol concentrations did not change significantly in any of the groups. Changes in cholesterol-standardized lathosterol concentrations were not significantly different between the three groups (P ¼ 0.860).
LDL-receptor mRNA
Expression of LDL-receptor mRNA did not change in the plant sterol and stanol groups as compared with the control group (P ¼ 0.929). The DDC T value for the control group was 1.1170.84 and for the experimental groups 1.1470.62.
Antioxidants and markers of endothelial function and low-grade inflammation
Plant sterol and stanol consumption did not affect LDLcholesterol-standardized concentrations of the hydrocarbon carotenoids (Table 4) , that is, a-carotene (P ¼ 0.273), b-carotene (P ¼ 0.815) and lycopene (P ¼ 0.320). Also, the sum of these hydrocarbon carotenoids (P ¼ 0.677) as well as concentrations of the other lipid soluble antioxidants (oxygenated carotenoids and tocopherols) did not change. With respect to the enzymatic antioxidants (Table 5) , plant sterol and stanol consumption did not affect RBC catalase (P ¼ 0.693) and SOD (P ¼ 0.742) concentrations or glutathione peroxidase (GpX) activity (P ¼ 0.606). Plant sterol and stanol consumption had no significant effects on markers of oxidative stress, that is, oxLDL, MDA, 15-PGDH and 8-oxo-dG concentrations. When changes in Effects of plant sterol and stanol ester consumption A De Jong et al concentrations of oxidized LDL were standardized for changes in apoB100, still no significant effects was found ( Table 6 ). Baseline oxLDL concentrations correlated with catalase concentrations (r ¼ 0.389, P ¼ 0.017) and GpX activities (r ¼ 0.606, Po0.001). Baseline CRP concentrations also correlated with catalase concentrations (r ¼ 0.523; P ¼ 0.001). No other significant correlations were found. The results for markers of low-grade inflammation, endothelial function and oxidative damage can be found in Table 6 . Plant sterol and stanol consumption did not change plasma concentrations of the soluble adhesion molecules ICAM, VCAM-1 and E-selectin. Also, plasma concentrations of MCP-1 and CRP were not significantly changed after the intervention period.
Discussion
In the present study, we found that despite a significant reduction in serum LDL cholesterol concentrations, plant sterol and stanol consumption for 16 weeks did not change markers of low-grade inflammation and endothelial function in subjects on stable statin therapy. Also, concentrations of lipid soluble and enzymatic antioxidants as well as markers reflecting oxidative modification of lipids and DNA, did not change.
Numerous intervention trials in healthy subjects as well as in various patient groups have consistently shown that plant sterol and stanol esters lower LDL cholesterol, when incorporated into a wide variety of food products. Several side-by-side comparisons further suggest that plant sterol and stanol esters are equally effective, at least in normo-and hypercholesterolemic subjects not using cholesterol-lowering medication (Hallikainen et al., 2000) ; (Weststrate and Meijer, 1998; Normen et al., 2000) . In seven ileostomy patients', for example, plant sterols and stanols (1.5 g/day) lowered cholesterol absorption to the same extent (Normen et al., 2000) . In hypercholesterolemic subjects, plant sterol or stanol consumption (2 g/day) resulted in a LDL cholesterol reduction of 10.4 and 12.7%, respectively (Hallikainen et al., Effects of plant sterol and stanol ester consumption A De Jong et al
2000)
. Finally, in normo-and mildly hypercholesterolemic subjects, plant sterols (3.2 g/day) and stanols (2.7 g/day) lowered LDL cholesterol by 13.1 and 11.9%, respectively (Weststrate and Meijer, 1998) . However, only two small studies have compared side-by-side the effects of plant sterol and stanol esters in subjects on statin therapy (Ketomaki et al., 2004 (Ketomaki et al., , 2005 . In five subjects with familial hypercholesterolemia (FH), plant stanol ester consumption (2 g/day) lowered LDL cholesterol by 14.6%. For plant sterol esters (2 g/day), a reduction of 16.4% was observed compared with baseline. In their second study in 18 FH subjects on statin therapy, plant stanol and sterol consumption (2 g/day) lowered LDL cholesterol by 15.3 and 14.2%, respectively (Ketomaki et al., 2005) . In our study -also a side-by-side comparison in subjects on stable statin treatment -LDL cholesterol was lowered by 12.6% in the plant stanol (2.5 g/day) and 8.1% in the plant sterol group (2.5 g/day) as compared with the control group. This response is smaller than that in the studies of Ketomaki et al. (2004 Ketomaki et al. ( , 2005 , whereas the intake of plant sterols and stanols was higher. However, in those studies there was no run-in period, which means that, unlike in our study, the response may include the effect of a change in background diet during the intervention. However, the most important aspect of these studies is that the combination of plant sterols or stanols with statins was more effective in terms of LDL-cholesterol lowering than could be expected from doubling the dose of statins. In general, this results only in an extra 5-7% LDL cholesterol reduction (Jones et al., 1998; Blair et al., 2000) . The mechanism by which plant sterols and stanols lower LDL cholesterol becomes more and more clear. It is well known that these components lower intestinal cholesterol absorption. To compensate for the reduced cholesterol flux into cells, both endogenous cholesterol synthesis and LDL receptor expression increase, at least in healthy subjects (Plat and Mensink, 2002a) . However, plant sterol and stanol consumption also lowers LDL cholesterol in FH children and adults (Ketomaki et al., 2005) who do not have functional LDL receptors. This indicates that these dietary components can lower LDL cholesterol independent of LDL-receptor upregulation. Moreover, in the study with FH adults (Ketomaki et al., 2005) , plant sterol and stanol consumption increased endogenous cholesterol synthesis despite statin treatment. This agrees with findings in non-statin-treated subjects and can be explained by the fact that statins do not completely block HMG-CoA reductase (Ketomaki et al., 2005) . In our study, LDL-receptor expression also did not change, whereas cholesterol synthesis was elevated -though nonsignificantly -by 42% in the plant sterol group and by 15% in the plant stanol group. The finding that serum LDL cholesterol can be decreased and endogenous cholesterol synthesis can increase, without a change in LDL receptor activity, seems controversial. The question then arises what mechanism can explain the observed LDL cholesterol reduction in our study. The most likely explanation may be found in the primary location of the cholesterol-lowering effect, that is, the intestine. We have earlier hypothesized that the effect of plant sterols and stanols on cholesterol is because of the effects inside the enterocytes; most likely they increase cholesterol efflux back into the intestinal lumen (Plat and Mensink, 2002b) . This can also occur in FH patients, as it does not involve LDL-receptor functioning.
The change in LDL-receptor expression and cholesterol synthesis can thus be seen as a consequence of the effects of plant sterols and stanols in the intestine and not as the cause of the serum LDL cholesterol reduction. Of course, the extent of the compensatory reactions, that is, elevated synthesis and LDL-receptor expression, may influence the overall reduction in serum LDL cholesterol concentrations. In addition to the primary effect in the intestine, a decrease in very low density lipoprotein (VLDL) synthesis can add to the cholesterol-lowering effect. As plant sterols or stanols decrease intestinal cholesterol absorption, less cholesterol will appear into the circulation and enter the liver. A smaller cholesterol pool is then available for incorporation into VLDL particles. However, this reduction in pool size will partly be compensated for by elevated endogenous cholesterol production. Whether VLDL production was changed at all and whether this effect does depend on statin treatment should be unraveled in future studies.
Plant sterol or stanol consumption can decrease plasma concentrations of the hydrocarbon carotenes: a-carotene, b-carotene and lycopene. As these fat-soluble antioxidants are carried by lipoproteins, correction for changes in total or LDL cholesterol concentrations is required. It has been estimated that at intakes of plant sterols or stanol 41.5 g/ day, total serum cholesterol standardized b-carotene concentrations decrease by 12.1% on average (Katan et al., 2003) . We hypothesized that the decrease in b-carotene would affect enzymatic antioxidant systems. However, concentrations of the fat-soluble diet-derived antioxidants did not change and also activity or concentrations of the enzymatic antioxidants GpX, SOD and catalase did not change. It is possible that the statin background of our subjects interfered with the effects of plant sterols or stanols on fat-soluble antioxidant concentrations. In a study of 12 months of statin therapy, after the first 12 weeks serum lipidsoluble antioxidants were reduced. After 52 weeks, however, Effects of plant sterol and stanol ester consumption A De Jong et al the b-carotene, a-tocopherol and g-tocopherol ratios to LDL--holesterol were normalized or even increased (Vasankari et al., 2004) . This may indicate that an interaction exists between statin treatment and antioxidant concentrations, which overrules effects of plant sterol or stanol consumption. Also, diet-sensitive markers of in vivo oxidative stress such as 8-oxo dG (DNA damage) and oxLDL, MDA and 15-PGDH (lipid peroxidation) did not change. Besides effects on serum lipoproteins, antioxidant concentrations and markers of in vivo oxidative stress, we also evaluated markers reflecting low-grade systemic inflammation and/or endothelial (dys)-function. No effects on plasma concentrations of sICAM, sVCAM-1, sE-selectin, MCP-1 and CRP were observed. As hypercholesterolemia is linked to endothelial dysfunction (Landmesser et al., 2000) , it can be hypothesized that lowering LDL cholesterol reduces the low-grade systemic inflammatory response and improves endothelial function, as has been shown for statins (Liao and Laufs, 2005) . Diet may also have favorable effects on markers of inflammation and endothelial dysfunction; however, like for statins (Comparato et al., 2001) , effects of diet on endothelial dysfunction may not only be due to LDL cholesterol-lowering properties but also to cholesterolindependent mechanisms. Favorable effects of diet on endothelial dysfunction has been shown for folate, isoflavones, a change in fatty acid content and composition of the diet and a Mediterranean diet (as reviewed by West, 2001 ). However, in the studies cited in this review, endothelial dysfunction was evaluated by markers different from those of the present study. It should be realized that endothelial dysfunction is a collective noun for disturbances of different physiological processes in the vascular wall, such as vascular tone, coagulation and inflammation (Cines et al., 1998) . This dysfunction can be measured by different methods and no uniform noninvasive marker exists that reflects all processes. Flow mediated dilation is a well-accepted measurement of endothelial dysfunction (Anderson et al., 1995) and seems mainly related to vascular tone. This parameter was also not changed in a study with prepubertal children with FH, who consumed plant sterol esters for 4 weeks (de Jongh et al., 2003) . However, no data are available for hypercholesterolemic adults. Soluble adhesion molecules may reflect the inflammatory response of the vessel wall (Granger et al., 2004) . Also, markers of coagulation have been used to measure endothelial dysfunction such as von Willebrand factor, plasminogen activatorinhibitor-1 and tissue-type plasminogen activator. Therefore, in future studies other markers that reflect the different aspects of endothelial dysfunction have to be explored.
In conclusion, plant sterol or stanol consumption effectively lowered serum LDL cholesterol concentrations in subjects on statin therapy that have a history of CVD and have increased endothelial dysfunction. No effects on lipidsoluble and enzymatic antioxidants, markers of DNA damage or lipid peroxidation, were observed. Despite the reduction in LDL cholesterol, markers of endothelial function and lowgrade inflammation did not change. Probably, (pleiotropic) effects of statin treatment may have overruled these effects. Similar studies in subjects without statin treatment should be initiated in the future to confirm or disprove this assumption.
